Autoimmune conditions associated with primary biliary cirrhosis: Response to ursodeoxycholic acid therapy

T. H. Zukowski, R. A. Jorgensen, E. R. Dickson, Keith Lindor

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: A variety of autoimmune conditions occur in association with primary biliary cirrhosis. Among these conditions are sicca syndrome, Raynaud's phenomenon, arthritis, and Hashimoto's thyroiditis. Information is sparse regarding the prevalence and natural history of these conditions when associated with primary biliary cirrhosis and their response to ursodeoxycholic acid treatment. We evaluated the prevalence, natural history, and response to ursodeoxycholic acid therapy of these conditions coassociated with primary biliary cirrhosis. Methods: One hundred-eighty patients with primary biliary cirrhosis, enrolled in a prospective randomized controlled trial of ursodeoxycholic acid (13-15 mg/kg/day), were included. Patients were assessed at study entry and annually. Results: At entry, 77/180 patients (43%) had one of the four conditions, and 18/180 patients (10%) had two or more conditions. Sicca syndrome was the most common, occurring in 58/180 patients (32%). After 2 yr, there was no difference between the treatment groups with regard to resolution or spontaneous onset of these autoimmune features. Sicca syndrome was the most common spontaneously developing condition (9% per yr). Sicca syndrome was the most common associated autoimmune condition, present in one-third of our patients. The associated conditions tended to improve over time, with a low rate of spontaneously developing these conditions. Although ursodeoxycholic acid therapy leads to improvement in the underlying liver disease, it did not appear to influence either the development or resolution of these autoimmune features. Conclusions: Although ursodeoxycholic acid is beneficial in the treatment of primary biliary cirrhosis, it had no measurable effect on the autoimmune conditions coassociated with the disease.

Original languageEnglish (US)
Pages (from-to)958-961
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume93
Issue number6
DOIs
StatePublished - Jun 1998
Externally publishedYes

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Sjogren's Syndrome
Natural History
Therapeutics
Hashimoto Disease
Raynaud Disease
Arthritis
Liver Diseases
Randomized Controlled Trials

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Autoimmune conditions associated with primary biliary cirrhosis : Response to ursodeoxycholic acid therapy. / Zukowski, T. H.; Jorgensen, R. A.; Dickson, E. R.; Lindor, Keith.

In: American Journal of Gastroenterology, Vol. 93, No. 6, 06.1998, p. 958-961.

Research output: Contribution to journalArticle

@article{05faf91d940540438af1b23eabad327f,
title = "Autoimmune conditions associated with primary biliary cirrhosis: Response to ursodeoxycholic acid therapy",
abstract = "Objectives: A variety of autoimmune conditions occur in association with primary biliary cirrhosis. Among these conditions are sicca syndrome, Raynaud's phenomenon, arthritis, and Hashimoto's thyroiditis. Information is sparse regarding the prevalence and natural history of these conditions when associated with primary biliary cirrhosis and their response to ursodeoxycholic acid treatment. We evaluated the prevalence, natural history, and response to ursodeoxycholic acid therapy of these conditions coassociated with primary biliary cirrhosis. Methods: One hundred-eighty patients with primary biliary cirrhosis, enrolled in a prospective randomized controlled trial of ursodeoxycholic acid (13-15 mg/kg/day), were included. Patients were assessed at study entry and annually. Results: At entry, 77/180 patients (43{\%}) had one of the four conditions, and 18/180 patients (10{\%}) had two or more conditions. Sicca syndrome was the most common, occurring in 58/180 patients (32{\%}). After 2 yr, there was no difference between the treatment groups with regard to resolution or spontaneous onset of these autoimmune features. Sicca syndrome was the most common spontaneously developing condition (9{\%} per yr). Sicca syndrome was the most common associated autoimmune condition, present in one-third of our patients. The associated conditions tended to improve over time, with a low rate of spontaneously developing these conditions. Although ursodeoxycholic acid therapy leads to improvement in the underlying liver disease, it did not appear to influence either the development or resolution of these autoimmune features. Conclusions: Although ursodeoxycholic acid is beneficial in the treatment of primary biliary cirrhosis, it had no measurable effect on the autoimmune conditions coassociated with the disease.",
author = "Zukowski, {T. H.} and Jorgensen, {R. A.} and Dickson, {E. R.} and Keith Lindor",
year = "1998",
month = "6",
doi = "10.1016/S0002-9270(98)00168-3",
language = "English (US)",
volume = "93",
pages = "958--961",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Autoimmune conditions associated with primary biliary cirrhosis

T2 - Response to ursodeoxycholic acid therapy

AU - Zukowski, T. H.

AU - Jorgensen, R. A.

AU - Dickson, E. R.

AU - Lindor, Keith

PY - 1998/6

Y1 - 1998/6

N2 - Objectives: A variety of autoimmune conditions occur in association with primary biliary cirrhosis. Among these conditions are sicca syndrome, Raynaud's phenomenon, arthritis, and Hashimoto's thyroiditis. Information is sparse regarding the prevalence and natural history of these conditions when associated with primary biliary cirrhosis and their response to ursodeoxycholic acid treatment. We evaluated the prevalence, natural history, and response to ursodeoxycholic acid therapy of these conditions coassociated with primary biliary cirrhosis. Methods: One hundred-eighty patients with primary biliary cirrhosis, enrolled in a prospective randomized controlled trial of ursodeoxycholic acid (13-15 mg/kg/day), were included. Patients were assessed at study entry and annually. Results: At entry, 77/180 patients (43%) had one of the four conditions, and 18/180 patients (10%) had two or more conditions. Sicca syndrome was the most common, occurring in 58/180 patients (32%). After 2 yr, there was no difference between the treatment groups with regard to resolution or spontaneous onset of these autoimmune features. Sicca syndrome was the most common spontaneously developing condition (9% per yr). Sicca syndrome was the most common associated autoimmune condition, present in one-third of our patients. The associated conditions tended to improve over time, with a low rate of spontaneously developing these conditions. Although ursodeoxycholic acid therapy leads to improvement in the underlying liver disease, it did not appear to influence either the development or resolution of these autoimmune features. Conclusions: Although ursodeoxycholic acid is beneficial in the treatment of primary biliary cirrhosis, it had no measurable effect on the autoimmune conditions coassociated with the disease.

AB - Objectives: A variety of autoimmune conditions occur in association with primary biliary cirrhosis. Among these conditions are sicca syndrome, Raynaud's phenomenon, arthritis, and Hashimoto's thyroiditis. Information is sparse regarding the prevalence and natural history of these conditions when associated with primary biliary cirrhosis and their response to ursodeoxycholic acid treatment. We evaluated the prevalence, natural history, and response to ursodeoxycholic acid therapy of these conditions coassociated with primary biliary cirrhosis. Methods: One hundred-eighty patients with primary biliary cirrhosis, enrolled in a prospective randomized controlled trial of ursodeoxycholic acid (13-15 mg/kg/day), were included. Patients were assessed at study entry and annually. Results: At entry, 77/180 patients (43%) had one of the four conditions, and 18/180 patients (10%) had two or more conditions. Sicca syndrome was the most common, occurring in 58/180 patients (32%). After 2 yr, there was no difference between the treatment groups with regard to resolution or spontaneous onset of these autoimmune features. Sicca syndrome was the most common spontaneously developing condition (9% per yr). Sicca syndrome was the most common associated autoimmune condition, present in one-third of our patients. The associated conditions tended to improve over time, with a low rate of spontaneously developing these conditions. Although ursodeoxycholic acid therapy leads to improvement in the underlying liver disease, it did not appear to influence either the development or resolution of these autoimmune features. Conclusions: Although ursodeoxycholic acid is beneficial in the treatment of primary biliary cirrhosis, it had no measurable effect on the autoimmune conditions coassociated with the disease.

UR - http://www.scopus.com/inward/record.url?scp=0032105455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032105455&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(98)00168-3

DO - 10.1016/S0002-9270(98)00168-3

M3 - Article

C2 - 9647028

AN - SCOPUS:0032105455

VL - 93

SP - 958

EP - 961

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -